Author/Authors :
Bou Ghosson Leite, Chilan Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil , Verissimo Ranzoni, Lucas Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil , Nogueira Giglio, Pedro Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil , Batista Bonadio, Marcelo Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil , da Ponte Melo, Lucas Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil , Kawamura Demange, Marco Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil , Gomes Gobbi, Riccardo Universidade de São Paulo - Faculdade de Medicina - Department of Orthopedics and Traumatology, São Paulo, SP, Brazil
Abstract :
Objective: To evaluate the profile of blood loss and blood transfu-
sions after the introduction of Tranexamic acid (TXA) in a tertiary
university hospital in Brazil. Methods: 173 patients were retrospec-
tively divided into two groups: the ones who received TXA and the
control group. Hemoglobin levels (Hb), drain output, transfusion
rates, and thromboembolic events were measured. Results: Among
the patients included in this study, 82 cases received TXA. Blood
transfusion occurred in 3 cases of the TXA group (3.7%), and in 27
control group cases (29.7%; p < 0.001). The average Hb decrease
was 2.7 g/dl (± 1.39) and the median drain output was 270 mL in the
TXA group. In the control group, the values were 3.41 g/dl (± 1.34;
p < 0.001) and 460 mL (p < 0.001), respectively. Thromboembolic
events occurred in 2 TXA group cases (2.4%) and in 3 control group
cases (3.3%; p > 0.999). Conclusion: TXA was effective in reducing
blood transfusion rates, Hb decrease, and drain output on the 1st
postoperative day without increasing thromboembolic events.
Level of evidence III, Retrospective comparative study
